---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-025304"
form_type: "8-K"
ticker: "KVAC"
cik: "0001889983"
company_name: "Keen Vision Acquisition Corp."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:46:48.964245+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# KVAC signs non-binding LOI to merge with Boston clinical-stage biopharma company

## Summary
- On March 22, 2024, KVAC entered a non-binding LOI for a potential business combination with a clinical-stage biopharma target.
- Target is based in Boston, U.S., focusing on stem cell bioengineering platform and next-gen cell/gene therapies.
- Target's several experimental gene therapies have FDA IND approvals and ongoing trials at multiple U.S. hospitals.
- LOI is non-binding and no definitive agreement has been executed; KVAC has until October 27, 2024 to close a business combination.
- Automatic six-month extension period available to KVAC upon execution of the LOI.

## SEC filing metadata
- accession: 0001213900-24-025304
- form_type: 8-K
- ticker: KVAC
- cik: 0001889983
- company_name: Keen Vision Acquisition Corp.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1889983/000121390024025304/0001213900-24-025304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1889983/000121390024025304/ea0202452-8k_keenvision.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-025304
- JSON: https://secwatch.observer/filing/0001213900-24-025304.json
- Plain text: https://secwatch.observer/filing/0001213900-24-025304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.